<DOC>
	<DOC>NCT03052634</DOC>
	<brief_summary>A significance,safety and pharmacokinetic of open-label and multicentric Phase Ib/II Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Breast Cancer</brief_summary>
	<brief_title>RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Signed informed consent form; Aged 1870 years； Eastern Cooperative Oncology Group(ECOG) physical condition is 0 or 1； Life expectancy greater than 12 weeks； Confirmed by histology or cytology，the patients who are HER2 positive, locally advanced or metastatic breast cancer，and who perform as having no effect on standard therapy (disease progression after treatment or treatment free remission) or intolerant of standard treatment or can not accept the standard treatment . Patients with locally advanced or metastatic advanced breast cancer diagnosed by pathology and refractory to standard of care therapy, or for whom no standard of care therapy is available histology standard of care therapy, or for whom no standard of care therapy is available； Documented Human epidermal growth factor receptor 2 (HER2)positive as measured either by immunohistochemistry (IHC 2+ and by fluorescence in situ hybridization (FISH)or by immunohistochemistry (score, 3+) ; Patients with measurable and appreciable tumor lesions according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) Adequate organ function as defined by the following criteria: （1）absolute neutrophil count(ANC) &gt;= 1.5 x 10(9)/L; (2) platelets&gt;=100*10(9)/L; (3)Total serum bilirubin &lt;=1.5*ULN; (4)serum aspartate transaminase (AST）and serum alanine transaminase (ALT) &lt;=2.5*upper limit of normal (ULN), or AST and ALT&lt;=5*ULN if liver function abnormalities are due to underlying malignancy; (5) Serum creatinine clearance rate &gt;= 45 mL/min; (6)international normalized ratio(INR) and activated partial thromboplastin time (aPTT) must be less than or equal to 1.5 times the upper limit of the normal range (ULN); Women of childbearing potential and men must agree to use adequate contraception (e.g., condoms, implants, injectables, combined oral contraceptives, some intrauterine devices, complete sexual abstinence, or sterilized partner) prior to study entry and during the period of therapy and for 30 days after the last dose of study drug. Left ventricular ejection fraction (LVEF) &gt;= 50% as assessed by echocardiogram. Current pregnancy or lactation. The patient received anticancer therapy within 4 weeks before study drug treatment;, including chemotherapy, radiotherapy, surgery or hormone therapy, molecular targeted therapy (including trastuzumab so on ), using Trastuzumab emtansine(TDM1) clinical study or participating in the clinical trial of the drug analogues. The patient have third interstitial fluid (a large number of pleural effusion or ascites) which is clinical symptom or can not be controlled by drainage or other methods; Received Palliative radiation therapy for bone metastases within 2 weeks before study drug treatment; Unresolved toxicities from prior anticancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version 4), grade less than or equal to1, or to the levels dictated in the inclusion/exclusion criteria with the exception of alopecia; Participated in clinical drug studies within 4 weeks; known hypersensitivity or delayed hypersensitivity to the some components of RC48ADC or similar drugs; the active infection with clinical significance according to the researcher's judgment, Known history of immune deficiency,including HIVpositive or other known acquired or congenital immunodeficiency, or organ transplantation; Unwilling or unable to participate in all required study evaluations and procedures. Serious complications such as diabetes ,interstitial pneumonia ,pulmonary fibrosis,hypertension and Acute lung disease; there are a variety of factors affecting medication intake and absorption such as unable to swallow, chronic diarrhea or intestinal obstruction; uncontrolled primary or metastatic tumor of brain; Patients who had received systemic steroid therapy for a long time(Patients who had received systemic steroid therapy for short time and stopped drug more than 2 weeks could be enrolled ); Preexisting peripheral neuropathy ≥ grade 2; History of nerve or psychiatric disorders; Cardiovascular disease problems includingAcute myocardial infarction， unstable angina, or myocardial infarction, stroke, transient ischemic attack or New York Heart Association (NYHA) grade 2 or more (including 2) of congestive heart failure within the last 6 months.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>